EGYPT – Ibnsina Pharma (ISPH) has entered into an exclusive distribution pact with global pharmaceutical company Boehringer Ingelheim.
Under the distribution pact, ISPH has agreed to distribute Boehringer Ingelheim’s biopharmaceutical innovations in Egypt.
The Cairo-based distributor will serve the Egyptian population with renowned pharmaceutical products covering essential disease areas, including type 2 diabetes, hypertension, respiratory diseases, and stroke.
Boehringer Ingelheim will leverage Ibnsina’s longstanding presence and experience in Egypt’s pharma market and its technical sales capabilities to improve patients’ access to advanced, preventive treatments and life-enhancing improvements.
Furthermore, it follows Ibnsina Pharma’s recent partnership with Sandoz Egypt Pharma, a division of the Novartis Group, for the distribution and promotion of the Sandoz over-the-counter (OTC) portfolio of products.
Ibnsina Pharma is the second-largest pharmaceutical distributor in Egypt, distributing products from over 350 global and local companies to more than 46,000 customers of pharmacies, hospitals, wholesalers, and healthcare institutions.
Its core services for suppliers include management of warehousing and logistics for pharmaceutical products as well as the development and execution of tailored marketing solutions targeting a nationwide database of customers.
Ibnsina Pharma’s primary competitors include AskGene Pharma, Fosun Pharma, and Harbin Pharmaceutical Group.
Following the agreement with Boehringer Ingelheim, the Cairo-based pharmaceutical distributor is well-positioned to withstand price competition from rivals.
“We are honored to partner with Boehringer Ingelheim and contribute to the company’s legacy in Egypt,” said Mohsen Mahgoub, Managing Director of Ibnsina Pharma.
He outlined that the recent agreement reflects Boehringer Ingelheim’s trust in Ibnsina Pharma’s ability to create new opportunities for increased health and well-being within the healthcare landscape in Egypt.
“We look forward to addressing patients’ unmet needs by delivering the latest medical treatments Boehringer Ingelheim has to offer the Egyptian market,” added Mahgoub.
Moreover, the partnership will enable Boehringer Ingelheim to expand its presence in Egypt, where it has been operating for more than six decades.
The German pharmaceutical company’s footprint in Egypt has been growing with a clear goal to transform the lives of patients in areas of significant unmet medical needs.
“Boehringer Ingelheim’s partnership with Ibnsina will further strengthen our leadership position in Egypt,” underscored Marianne Abou Elkheir, General Manager and Head of Human Pharma at Boehringer Ingelheim for Levant, Iraq, North East Africa (LINEA) and Sub Saharan Africa (SSA).
She pointed out that the partnership reiterates Boehringer Ingelheim’s commitment to delivering sustainable solutions and treatments to the patients its serves.
“We are confident that, along with Ibnsina, we will bring the best of our collective expertise and in-market knowledge to provide quality healthcare to patients,” Marianne added.